Anti-ErbB4 targeting approaches for prostate cancer treatment

Vexler, Akiva; Lidawi, Ghalib; Loew, Leslie M.; Barnea, Itay; Karaush,; Lev-Ari, Shahar; Shtabsky, Alexander; Ben‐Yosef, Rami

doi:10.4161/cbt.7.7.6167

Cited by 8 publications

(3 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…C-erbB-4 antibodies were able to delay the growth of several PCa in vitro and in a mouse xenograft model [169,170]. In addition, c-erbB-4-directed mAb treatment could be improved by concomitant radiation therapy [170]. …”

Section: Proteins Overexpressed In Various Tumors Including Prostamentioning

confidence: 99%

Tumor-Associated Antigens for Specific Immunotherapy of Prostate Cancer

Kießling

Wehner

Füssel

et al. 2012

Cancers

View full text Add to dashboard Cite

Prostate cancer (PCa) is the most common noncutaneous cancer diagnosis and the second leading cause of cancer-related deaths among men in the United States. Effective treatment modalities for advanced metastatic PCa are limited. Immunotherapeutic strategies based on T cells and antibodies represent interesting approaches to prevent progression from localized to advanced PCa and to improve survival outcomes for patients with advanced disease. CD8+ cytotoxic T lymphocytes (CTLs) efficiently recognize and destroy tumor cells. CD4+ T cells augment the antigen-presenting capacity of dendritic cells and promote the expansion of tumor-reactive CTLs. Antibodies mediate their antitumor effects via antibody-dependent cellular cytotoxicity, activation of the complement system, improving the uptake of coated tumor cells by phagocytes, and the functional interference of biological pathways essential for tumor growth. Consequently, several tumor-associated antigens (TAAs) have been identified that represent promising targets for T cell- or antibody-based immunotherapy. These TAAs comprise proteins preferentially expressed in normal and malignant prostate tissues and molecules which are not predominantly restricted to the prostate, but are overexpressed in various tumor entities including PCa. Clinical trials provide evidence that specific immunotherapeutic strategies using such TAAs represent safe and feasible concepts for the induction of immunological and clinical responses in PCa patients. However, further improvement of the current approaches is required which may be achieved by combining T cell- and/or antibody-based strategies with radio-, hormone-, chemo- or antiangiogenic therapy.

show abstract

Section: Proteins Overexpressed In Various Tumors Including Prostamentioning

confidence: 99%

Tumor-Associated Antigens for Specific Immunotherapy of Prostate Cancer

Kießling

Wehner

Füssel

et al. 2012

Cancers

View full text Add to dashboard Cite

show abstract

“…A significant proportion of PCa cases exhibited elevated EGFR levels, which has been associated with the progression of PCa towards androgen independence. In vivo trials administering EGFR-specific monoclonal antibodies cetuximab and panitumumab have demonstrated the suppression of cancer development in multiple prostate cancer xenograft models [111,200] . Despite EGFR primarily being investigated as a target for monoclonal antibodies, several CTL epitopes have been found [111,201] .…”

Section: Her-2/neu Egfr Her-4 (Epidermal Growth Factor Family)mentioning

confidence: 99%

New approaches and prospects of immunotherapy and gene therapy for prostate cancer

Bibi,

Sarkar

2024

J Transl Genet Genom

View full text Add to dashboard Cite

Prostate cancer stands as the most prevalent cancer globally, constituting 21% of all cancer diagnoses in male patients. Urgent optimization of prostate cancer care is essential, given that this disease claims 345,000 lives every year. These innovative approaches hold substantial promise for both researchers and patients, representing a beacon of hope in the inhibitory act against prostate cancer. Prostate cancer's gradual advancement deems it suitable for immune therapy, but trials in metastatic cases show limited effectiveness, likely due to compromised immunity. Hindered by defective cellular responses, an immune-suppressive microenvironment, emerging evidence and breakthroughs, such as CAR-T therapy, inspire cautious optimism for advanced prostate cancer immunotherapy. Tumors utilize tactics to escape immune recognition, promoting the proliferation of MDSCs, Treg cells, and TAMs. Immunotherapy targets prostate cancer by mostly expressed target proteins and overexpressed target proteins. Immune cells play a role in tumor development and metastasis in advanced prostate cancer. Modulating the tumor microenvironment presents therapeutic possibilities. Certain prostate cancer types exhibit potential responses to immune checkpoint inhibitors, yet obstacles remain, necessitating additional research for enhanced efficacy. Immunotherapy faces hurdles in prostate cancer—limited inflammation, scarce antigens, and a resistant microenvironment. Grasping resistance intricacies is pivotal. The identification of DNA's helical structure propelled global progress in disease treatment through gene therapy. Choosing gene therapy vectors is critical; viruses are potent but toxic, while nonviral options, though less toxic, encounter barriers affecting transfection. In the realm of prostate cancer treatment, immunotherapy and gene therapy are emerging as increasingly viable options.

show abstract

“…Worth mentioning is also that an antibody-based HER4 targeting is also subject of investigation within other fields of cancer research such as lung [105] or prostate cancer [108,109].…”

Section: The Potential Of Therapeutic Anti-her4 Targetingmentioning

confidence: 99%

“Shedding” light on HER4 signaling in normal and malignant breast tissues

Brockhoff

2022

Cellular Signalling

View full text Add to dashboard Cite

Anti-ErbB4 targeting approaches for prostate cancer treatment

Cited by 8 publications

References 14 publications

Tumor-Associated Antigens for Specific Immunotherapy of Prostate Cancer

Tumor-Associated Antigens for Specific Immunotherapy of Prostate Cancer

New approaches and prospects of immunotherapy and gene therapy for prostate cancer

“Shedding” light on HER4 signaling in normal and malignant breast tissues

Contact Info

Product

Resources

About